Navigation Links
PD-Rx Completes Call for Preferred A Stock
Date:8/8/2008

OKLAHOMA CITY, Aug. 8 /PRNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc., a publicly held corporation, (Pink Sheets: PDRX) today announced that it has completed a repurchase of all of its outstanding Preferred "A" stock.

The outstanding Preferred Shares of Class "A" 13.25% Cumulative Convertible Stock representing One Hundred and Sixty Five Thousand (165,000) shares has been repurchased by PD-Rx Pharmaceuticals, Inc. The stock call represents PD-Rx's position to improve the company's financial status, while creating an advantageous move for its common shareholders.

All outstanding share of the Preferred Class "A" Stock has been redeemed and will be delisted.

ABOUT THE COMPANY:

PD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers and healthcare providers as a progressive and responsive practice.

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic con
'/>"/>

SOURCE PD-Rx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...Finding and treating a tumor without disturbing no...t effective therapies can be invasive and harsh. ,...ave devised a way they might deliver the right the...alled aptamers, which specifically bind to living ...tamers in a rodent with liver cancer until they fo...
(Date:11/30/2009)... According to Steven McConnell, DDS, teac...ng flu season is a good idea, but brushing their t...ally coming down with a virus. , ...the California Dental Hygienists’ Associatio...ween oral health and flu prevention because the H1...
(Date:11/30/2009)...AGO, Nov. 30 Three decades ago, a ...ing swallowed by children, prompting a switch by U...ted today at the annual meeting of the Radiologica...ew tabs are still potentially unsafe. ,, "One o...ge can construction in the U.S. was to eliminate i...
(Date:11/30/2009)... decades ago, a study revealed that beverage can p...ng a switch by U.S. manufacturers to stay-tabs. Bu... the Radiological Society of North America (RSNA) ...fe. , "One of the driving factors leading the ch...to eliminate inadvertent swallowing of the pull-ta...
(Date:11/29/2009)... Moravia,s Nanjing-based Service Delivery...e , Brno, Czech Republic ...ion solution provider, is pleased to announce its ...2009, to be held in Nanjing, China, on November 30...nion-based companies that have established and gro...
Breaking Medicine News(10 mins):Health News:First live targeting of tumors with RNA-based technology 2Health News:First live targeting of tumors with RNA-based technology 3Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 2Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 3Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 4Health News:Beverage Can Stay-Tabs Pose Swallowing Risk 2Health News:Beverage can stay-tabs pose swallowing risk 2Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2
...previously noted low rates of successful hepatitis... large part due to very early differences in the a...y is published in the April 15 issue of the Journ...f the population is infected. Chronic HCV infectio...
...ups, survival odds after angioplasty are not as gr...-- A major international study pinpoints which peo...ter off having bypass surgery than artery-opening ...cy and cardiovascular medicine at Stanford Univers...
...ng Helps Mainstream Management Process , , STUART... Health Systems, a not-for-profit, community-based...Florida, needed a way to track potential conflicts...ncommon for outside interests and business prospec...
...ta Barbara, California, offshore oil spill gave bi... States a leader in environmental protection world...n a key issue to both industrial and environmental...ciety. , In his new book, The Conflict over Envi...
...e Savvy Self-Funding Healthcare Conference and Exp...the opportunity to discuss creative healthcare opt...City, Missouri. , , This unique conference is des...nt to help educate employers and plan sponsors on ...
...versity, together with colleagues at the Karolinsk...nd all the genes the determine the dosage of the b...ished in the scientific journal PLoS Genetics . ,...he two most important genes are among those we pre...
Other Medicine News:Health News:2-day results predict ultimate response to therapy in chronic hepatitis C 2Health News:Diabetics and Elderly May Fare Better With Bypass 2Health News:Diabetics and Elderly May Fare Better With Bypass 3Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 2Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 3Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 4Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 5Health News:An even-handed analysis of environmental policy 2Health News:Deffenbaugh Industries to Host Self-Funding Healthcare Conference in Kansas City 2
(Date:11/30/2009)..., , RICHMOND, Va., Nov. 30 /PRNewswire/ -...icense with sanofi-aventis U.S. for a novel epinep...ory. Under the license, sanofi-aventis U.S. shall ...tion. Intelliject will be responsible for the on-g... approval and has retained certain co-promotion ri...
(Date:11/30/2009)..., , ATLANTA, G...College of,Direct Support (CDS), an internet-based...anaged in partnership by MC Strategies/Elsevier an...ining Center, announced today that,its second Disa...is now,available for administrators and learners t...
(Date:11/29/2009)..., , CHICAGO, Nov. 30 Middl...physical activity may be unknowingly causing damag...eoarthritis, according to a study presented today ...of North America (RSNA). ,, "Our data suggest t...y be at greater risk for developing knee abnormali...
Breaking Medicine Technology:Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 2Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 3Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 2Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 3Too Much Physical Activity May Lead to Arthritis 2Too Much Physical Activity May Lead to Arthritis 3Female Supervisors More Likely to Be Sexually Harassed 54300 1Female Supervisors More Likely to Be Sexually Harassed 54300 2Female Supervisors More Likely to Be Sexually Harassed 54300 3September is Prostate Cancer Awareness Month 54295 1September is Prostate Cancer Awareness Month 54295 2Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 54292 1Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 54292 2
...il 29 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA... clinical trial of AZ-007 (Staccato(R) zaleplon). ...veloped for the treatment of insomnia,patients who...s who awake,in the middle of the night and have di... product candidate using our single-dose Staccato,...
...and multi-lesion clinical trial data to be pre..., May 13, MENLO PARK, Calif., April 28 XTENT, In...ts for the first quarter ended,March 31, 2008., T...r $0.54 per share,for the first quarter of 2008, c...r share, for the first quarter of 2007. The compan...
Other Medicine Technology:Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 2Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 3Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 4XTENT Announces First Quarter 2008 Financial Results 2XTENT Announces First Quarter 2008 Financial Results 3XTENT Announces First Quarter 2008 Financial Results 4XTENT Announces First Quarter 2008 Financial Results 5
Replacement Bulb: HBO 100W/2
Replacement Bulb: FCS
Replacement Bulb: ELH
Replacement Bulb: EJA
Medicine Products: